Overview

TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine whether TRI102 is effective in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children ages 6-12.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Tris Pharma, Inc.
Treatments:
Amphetamine
Criteria
Inclusion Criteria:

- Children aged 6 to 12 years with ADHD who require pharmacologic treatment for this
condition

Exclusion Criteria:

- Other serious illnesses or conditions that would put the patient at particular risk
for safety events or would interfere with treatment/assessment of ADHD